As the current Chief Executive Officer of Target RWE, Derek Evans is an accomplished business professional with more than 25 years of healthcare and software analytics experience. Most recently, Derek was the General Manager of Decision Analytics and Innovation at Change Healthcare, where he was instrumental in the creation and strategy of their healthcare analytics platform.
Prior to Change Healthcare, Derek served as the SVP and General Manager of Patient Informatics at Symphony Health Solutions, an Icon plc company, where he led the Commercial Effectiveness and Brand Analytics consulting businesses. Over his career, Derek has worked with his colleagues and clients to develop groundbreaking solutions that have unlocked billions of dollars in incremental revenue. He has focused his expertise on all facets of the healthcare system to bring cohesive, integrated and essential solutions that help improve care delivery.
Derek holds an MBA in marketing and finance from the Fox School of Business at Temple University and a BS in biochemistry and cell biology from Clarkson University.
Michael W. Fried, MD, FAASLD
Co-Founder & Chief Medical Officer
Dr. Fried is Chief Medical Officer and Co-Founder of Target RWE. He is also Professor of Medicine at the University of North Carolina at Chapel Hill and Past-President of the American Association for the Study of Liver Diseases (AASLD). Dr. Fried trained at the State University of New York at Syracuse and the National Institutes of Health, Bethesda, MD, which provided him with the foundation for his 30 years of experience in clinical and translational research. Dr. Fried is co-author of 200+ publications in the field of liver disease and is currently co-chair of the NIH Hepatitis B Research Network. He is co-principal investigator of the HCV-TARGET network which was awarded the FDA Excellence in Regulatory Science Award for contributions to optimizing management for hepatitis C.
M. Alan Brookhart, PhD
Chief Scientific Officer
Alan is a biostatistician and an epidemiologist who has spent the last 15 years developing and applying epidemiological and statistical methods for studies using real-world healthcare data. He has more than 200 publications in leading journals in medicine, biostatistics, and epidemiology. Alan joined in 2021 when Target RWE acquired his company NoviSci, Inc. At Target RWE, Alan oversees the Epidemiology & Statistics departments and helps catalyze new projects, ideas for analytic software, visualization tools, and research methodology.
Alan is also a Professor in the Department of Population Health Sciences at Duke University, an Adjunct Professor at UNC Chapel Hill, and an Honorary Professor of Clinical Epidemiology at the University of Aarhus, Denmark. Previously Alan was on faculty at Harvard Medical School and was also a co-founder and chair of the scientific advisory board of RxAnte, Inc., a provider of widely used predictive analytics for decision support. Alan is a member of many scientific advisory groups, review panels, and editorial boards.
Chief Data & Analytics Officer
Rob Sullivan joined Target RWE in 2020 to serve as its Chief Data & Analytics Officer, bringing to the team a great deal of experience in the healthcare industry with prior executive level positions at Symphony Health Solutions, Focus Diagnostics (now part of Quest Diagnostics and Eurofins), and IMS Health. In addition, Rob has worked in technical and statistical roles with various pharmaceutical companies in the drug development and commercial phases.
Joy Peter, RN, BSN
Vice President, Evidence Solutions
Joy Peter is the Vice President of Evidence Solutions at Target RWE. Prior to her current role, Joy served as Associate Director of the HCV-TARGET Network at the University of Florida (UF) where she worked with co-founder Dr. Fried to develop a large international network of 50+ academic and community investigators partnered with the FDA, HCV patient advocacy groups to follow outcomes and rapidly inform clinical practice in patients treated for HCV. Joy helped design several other innovative studies within HCV-TARGET including a large, pragmatic PCORI study, multiple post-marketing commitment and post authorization studies as well as protocols to pair clinical data to biospecimens.
Outside of Target RWE, Joy’s expertise includes more than 20 years of clinical research experience as a nurse with subject matter expertise in liver disease and broad knowledge from her role as Associate Director of Hepatology Clinical Research at UF since 2002.
Greg Pate, JD
General Counsel and Vice President, Legal, Compliance, and Quality Assurance
Greg joined Target RWE in 2022 as Vice President and General Counsel where he leads the Legal, Compliance and Quality Assurance functions. He brings to Target RWE more than 20 years of experience in the healthcare industry, spanning the health data, CRO, pharmaceutical and medical device sectors.
Greg earned his J.D. from the University of North Carolina at Chapel Hill and his B.A. in Biology from the University of North Carolina at Greensboro.
Vice President, Enterprise Architecture
Viswa has more than 19 years of proven experience spanning analytics, machine learning, application development, and software engineering. Most recently, he served as VP of Architecture and R&D at Symphony Health Solutions where he architected and built various machine learning and analytics toolsets.
In his past experience, Viswa has designed and developed several complex systems including “The (Microbiology) Surveillance Network”, Electronic Lab, and Clinical Analytics Architecture framework. Viswa earned his degree in electrical engineering; however, his professional experience has focused on healthcare and life sciences.
Matt Roth, CPA, MBA
Vice President, Finance
Matt brings more than 20 years of experience in working in the finance/accounting industry with positions in the pharmaceutical, CRO, software, and government sectors that included publicly traded and private equity-backed enterprises.
Prior to joining Target RWE, Matt spent more than 2 years as an Engagement Director for CliftonLarsonAllen where he provided technical accounting services and executed system implementations for clients in the banking and services industries. He completed his Bachelor of Accounting degree from DeSales University and received his Executive MBA from Drexel University’s LeBow College of Business.
Senior Director, Human Resources
Tara Bridgeman is the Sr. Director, Human Resources for Target RWE. Tara brings 20+ years of Human Resources experience to the company. Prior to joining Target RWE Health Evidence Solutions, Tara was the Vice President of Human Resources at Dude Solutions where she was responsible for leading the people, culture, and human resources operational initiatives. Prior to Dude Solutions, Tara additionally held numerous leadership roles at Blue Cross Blue Shield of NC where she was accountable and in charge of executing the talent and staffing strategies, building the employee relations function, and overseeing HR compliance.
Ewa J. Kleczyk, PhD
Senior Vice President, Commercial Analytics & Data Curation
Ewa J. Kleczyk, PhD is a Senior Vice President of Commercial Analytics & Data Curation at Target RWE. Previously, she was a Vice President of Advanced and Custom Analytics at Symphony Health, ICON, plc, leading commercial analytics applications and operations. With nearly 20 years of experience, Dr. Kleczyk has been healthcare industry’s analytics and operations leader with a proven record for establishing high performing teams and delivering innovative analytics solutions. Her experience spans across real-world evidence, data science, health economics, outcomes research, brand and managed market analytics, digital & media analytics, as well as forecasting & promotional impact measurement.
Dr. Kleczyk is also a highly sought-after conference speaker with experience speaking at leading industry conferences, including presentations at Pharmaceutical Marketing Sciences Association, Intellus, DTC Perspectives, CDM Media, Pharmaceutics & Novel Drug Delivery Systems, and Conference for Business and Economics at the Harvard University, etc. She also has published in multiple academic & industry journals, contributed chapter to several books as, well as has been a board member of several peer-reviewed publications.
Dr. Kleczyk has been an active advocate of mentoring future women leaders of the pharmaceutical industry for which she has been recognized with multiple leadership awards, including HBA’s ‘Rising Star’ & ‘Luminary’ recognitions. She is also a Board Member on the Community Cancer Council in Bangor, ME. that provides advocacy for cancer patients, and a graduate faculty in the School of Economics at the University of Maine, Orono, ME.
Dr. Kleczyk earned her Doctorate Degree in Agricultural and Applied Economics from Virginia Tech, Blacksburg, VA, as well as MS in Resource Economics and Policy and BA in Economic from the University of Maine, Orono, Maine.
Meg Powell, PharmD, MBA
Co-Founder & Board Chair
Meg Powell has over 15 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lilly and GlaxoSmithKline. She is currently serving as Board Chair and is the Co-Founder of Target RWE.
Meg has worked with multiple start-up companies while at Medgility, a consulting firm focused on strategy and business development of emerging companies. These include Qura Therapeutics, KemPharm, Inc, and most notably, Aerial Biopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals.
Prior to her work at Medgility, Meg was Vice President of the US Transformation Office at GlaxoSmithKline. She has in depth experience in sales and marketing for US and global development programs at all stages – from phase 1 to post patent expiry.
Meg received her Doctorate of Pharmacy degree from the University of North Carolina- Chapel Hill where she was a Hollingsworth Scholar. She also received a Master’s of Business Administration from Stanford University.
Eric Edell is Co-Founder and Co-Managing Partner of 22C Capital, a private equity firm committed to delivering capital and critical resources to companies operating at the intersection of technology enablement and data analytics adoption. The Firm has a dedicated focus on the healthcare services, business services, and financial services sectors. 22C's operational and technology resources, including its affiliated data science organization strive to deliver practical, real-world support to help convert these businesses' challenges into opportunities and unlock their full potential.
Mr. Edell received his B.A. in Neuroscience, summa cum laude, from the University of Pennsylvania, where he was a member of Phi Beta Kappa. He lives in Florida with his wife, Deborah, and their three children.
Ryan A. Harris, MD
Ryan Harris, MD brings more than twenty-five years of healthcare experience and fifteen years as a growth equity and buyout investor. Combining deep medical knowledge and extensive strategic business experience, Ryan focuses on growth equity investments in the healthcare sector in Norwest’s Palo Alto office. Areas in which he invests include healthcare services, pharma services, healthcare IT, medical devices. Ryan’s current investments include Blue Cloud, Onsite Dental, and Rivermend Health. His previous investments include Capsugel (acquired by Lonza), Crossover Health (acquired by Gurnet Point Capital), and iCardiac (acquired by ERT).
Prior to joining Norwest, Ryan was a Principal with The Carlyle Group and a Venture Partner with Industry Ventures, where he focused exclusively on healthcare services, pharmaceutical, and medical device investments from large cap buyouts to growth equity and venture.
At Carlyle, Ryan’s deals led to realized profitable exits of more than $2.2 billion equity value. He served as a member or observer on the Board of Directors of Align Technologies (Nasdaq: ALGN), AqueSys, Colin Medical, ConnectiCare, MedPointe Pharmaceuticals, Multiplan, NeoVista, Proteus Biomedical and Qualicaps.
At Industry Ventures, Ryan executed transactions involving Access Closure, Cardiofocus, Ingenuity, and Intarcia. Prior to joining Carlyle in 2002, Ryan was a consultant in the West Coast Healthcare Practice of McKinsey & Company, where he worked with a variety of biotechnology, pharmaceutical and medical device companies on corporate, R&D and marketing strategies.
Ryan has authored more than 25 peer-reviewed comparative effectiveness articles in publications such as JAMA, Lancet, Annals of Internal Medicine, and the Journal of Health Economics.
Dr. Harris holds an M.D. from the University of California, San Francisco, School of Medicine. In addition, he earned an M.S. in health research and policy, and a B.A. in psychology from Stanford University. Ryan also attended Oxford University’s Magdalen College.
Colleen Coda is a Partner at 22C Capital. Prior to joining 22C, she was Managing Director within Blackstone’s Technology and Innovations group (BXTI). She joined Blackstone in 2011 to build a world class technology organization to drive digital transformation that enabled growth, scale and efficiencies across all aspects of the Firm. While at Blackstone, Colleen held a number of positions, most recently as CTO of several business units including the core Private Equity unit (encompassing seven different investment segments and Portfolio Operations). In addition to her CTO roles, she also oversaw a variety of programs across BXTI including chairing the Diversity and Inclusion Committee, running Product Management and helping run the Technology Innovations Fund which made investments in early stage technology companies. She also led the initiative to consolidate consulting firms into a strategic offshore center that provided services and capabilities across technology, finance and other business functions and grew to over 300 people in India under her leadership.
Colleen was also a member of the Blackstone firmwide Diversity Champion Committee. Prior to joining Blackstone, Colleen was at Capital IQ for 11 years where her last role was Co-CTO focused on Product Development. In this role she was responsible for the strategic product roadmap working across Data & Analytics, Sales, Marketing, and Technology to align the vision of the product all the way through execution. Colleen received her B.S. in Computer Science from Sacred Heart University. She lives in NJ with her husband, Ed, and their three children.
Franz Humer, PhD
Dr. Humer is Chairman of the Board of Directors of the International Centre for Missing & Exploited Children and Chairman of the Humer Foundation. He is also a Non-Executive Director of the Board at Allogene Therapeutics, the Chairman of PCI Services and an Advisor to Temasek Holdings and Letterone Healthcare.
Before joining Roche Group, he was the managing director of Glaxo Pharmaceuticals UK Ltd. and was elected to the Board of Glaxo Holdings plc where he progressed to be responsible for research, business development, manufacturing, commercial strategy, and all non-U.S. operations for 13 years. In 1973, Franz joined Schering-Plough Corporation, where he held various general management positions in Latin America and Europe. In 1995, he joined Hoffmann-La Roche as a member of its Board and the head of its pharmaceuticals division, becoming Chairman and CEO in 2001 and Chairman of Roche Holding Limited between 2008 and 2014. Franz joined the Board of Diageo in 2005, became Chairman in 2008 and retired in 2016. Franz earned a PhD in law from the University of Innsbruck and an MBA from INSEAD in Fontainbleau, France.
Andrew von Eschenbach, MD
Dr. von Eschenbach serves on the Board of Directors of the Reagan-Udall Foundation for the Food and Drug Administration. He is currently President of Samaritan Health Initiatives, a private consulting firm that focuses on improving the ecosystem for the discovery, development, and delivery of innovative 21st century solutions to eliminate disease and restore health, and an Adjunct Professor at the University of Texas UT MD Anderson Cancer Center. In addition, Dr. von Eschenbach is a Senior Fellow and Board member of various research institutions, pharmaceutical and healthcare companies. From 2006 to 2009, Dr. von Eschenbach served as Commissioner of the U.S. Drug and Food Administration, after being appointed Acting Commissioner in 2005. Prior to that, he served as Director of the National Cancer Institute from 2002 to 2006, after spending 26 years at the University of Texas M.D. Anderson Cancer Center, including as Director, Genitourinary Cancer Center.
Dr. von Eschenbach received a B.S. in biology from St. Joseph's University and a MD from Georgetown University School of Medicine.